Navigation Links
Odyssey Thera to Participate in Expanded EPA Initiative
Date:12/6/2010

SAN RAMON, Calif., Dec. 6, 2010 /PRNewswire/ -- The United States Environmental Protection Agency (EPA) announced today a new phase of toxicity screening, in which 1,000 chemicals will be screened as part of EPA's ToxCast initiative. Odyssey Thera's participation in this program, first announced earlier this year, involves the application of extensive and diverse proprietary assay and screening technologies. "The Odyssey team is very pleased with our contributions to ToxCast to date, and we're excited to see this program accelerating," said Dr. Jane E. Lamerdin, Executive Director of R&D at Odyssey Thera, "ToxCast represents an ideal application of our validated chemical analysis strategies."

The chemicals will be assessed for potential toxicity to people and the environment. ToxCast is designed to determine how chemical exposures impact human biological processes and how the chemicals most likely lead to health effects. When fully implemented, ToxCast will be able to screen thousands of chemicals in fast, cost-effective tests that are relevant to human health. The chemicals being tested are found in industrial and consumer products, food additives and drugs that never made it to the market.

The full news release can be found at: http://yosemite.epa.gov/opa/admpress.nsf/d0cf6618525a9efb85257359003fb69d/73ec2518e34bc93d852577eb0060dd7c!OpenDocument. More information on ToxCast and the list of chemicals can be found at http://www.epa.gov/comptox.

About Odyssey Thera, Inc.

Odyssey Thera, Inc. is a privately held drug discovery technology company focused on improving the success rate of new therapeutic development. Odyssey Thera's technology measures disease–relevant pathway activity within living human cells. Odyssey is leveraging its proprietary drug di
'/>"/>

SOURCE Odyssey Thera, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Stereotaxis Launches the Odyssey Interventional Network for Superior Online Cardiovascular Education and Training
2. Stereotaxis and Siemens Promote Integrated Odyssey(TM) Solutions
3. Odyssey Thera Announces Achievement of Pfizer Drug Candidate Milestones
4. Nile Therapeutics Receives NASDAQ Notice; Will Request Hearing
5. Elekta Receives FDA 510(k) Clearance for XiO Software to Plan Spot Scanning for Proton Therapy
6. Halozyme Therapeutics Realigns Management
7. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
8. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
9. SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies
10. VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy
11. Neuro Kinetics Receives HHS Therapeutic Discovery Grant to Further Research Into Early Diagnosis of Sports Concussions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015 Today, Kenneth ... Merck & Co., Inc., was elected chairman of the Board ... today,s Board meeting, PhRMA,s president and CEO John J. ... 1, 2016.  New Officers Elected to PhRMA ... and succeeds Ian C. Read , chairman and CEO ...
(Date:4/16/2015)... April 16, 2015  Rosewind Corporation (OTCMKTS: RSWN) ... merger with a newly formed specialty healthcare company ... on addressing urological disorders. The merged company, which ... has commenced operations and incorporates the pipeline assets ... Company,s strategy is to build a late-stage and ...
(Date:4/16/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/qvd3lm/cancer_growth ) ... Growth Inhibitors Market & Clinical Pipeline Analysis " ... growth inhibitors market shows overlapping boundaries due to ... For instance, a tyrosine kinase may be a ... have same inhibitory molecule. On the other hand, ...
Breaking Medicine Technology:Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 5Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 2Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 3Global Cancer Growth Inhibitors Market & Clinical Pipeline Analysis 2015 2Global Cancer Growth Inhibitors Market & Clinical Pipeline Analysis 2015 3
... 28, 2011 Uroplasty, Inc. (NASDAQ: UPI ), ... proprietary products to treat voiding dysfunctions, today reported financial results ... 2011. Global sales grew 53% to $4.7 million ... with $3.0 million in the fiscal first quarter a year ...
... 28, 2011 Codexis, Inc. (Nasdaq: CDXS ... wholly-owned by Italy,s Gruppo Mossi & Ghisolfi ("M&G Group"), ... sustainable detergent alcohols for use in the household products ... alcohols from cellulosic (non-food) biomass. Detergent alcohols ...
Cached Medicine Technology:Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012 2Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012 3Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012 4Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012 5Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012 6Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012 7Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012 8Codexis and Chemtex to Collaborate on Sustainable Detergent Alcohols for the Household Products Market 2Codexis and Chemtex to Collaborate on Sustainable Detergent Alcohols for the Household Products Market 3Codexis and Chemtex to Collaborate on Sustainable Detergent Alcohols for the Household Products Market 4
(Date:4/17/2015)... April 17, 2015 Representatives Jim Himes ... and Treatment Act HR 1849 in congress on April ... and treatment for patients with the genetic disease. ... past, would be the first to create a federally ... treatment of hereditary hemorrhagic telangiectasia. This would effectively prevent ...
(Date:4/17/2015)... 17, 2015 As a board-certified orthopedic ... new offering of platelet-rich plasma (PRP) and ... is known for its world-class care of injury-caused ... surgical experience lacking in many other physicians offering regenerative ... are utilized for pain management and rehabilitation. Dr. Meier ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Most dental ... dental restoration units are made overseas by foreign dental ... domestic labs remain unregulated in more than 40 states ... National Association of Dental Laboratories has created ... raise awareness among patients about the consequences that could ...
(Date:4/17/2015)... Baptist Health and The University of Texas MD ... to transform oncology care in northeast Florida and southeast ... a joint cancer program to enhance patient access to ... Anderson Cancer Center is anticipated to open in the ... coordinated, multidisciplinary cancer care for adults in the region. ...
(Date:4/17/2015)... York, NY (PRWEB) April 17, 2015 ... collaborating with a multicenter team of U.S. and ... of bacteria yet in humans among an isolated ... jungles of Venezuela. Bacterial diversity in the Yanomami, ... found to be nearly double that of people ...
Breaking Medicine News(10 mins):Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:National Association Urges Transparency in Dental Industry 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3
... devouring billions of dollars globally, Alzheimer,s disease is the ... Although intensely investigated over the last three decades using ... not been found. While many research "breakthroughs" have ... does the promised "cure" still seem to elude scientists? ...
... (HealthDay News) -- Good news for high-mileage runners: They may be ... because variations in diet are less likely to affect them, researcher ... grouped according to the distance they run each day: less than ... to 4 km); 2.4 to 3.7 miles (4 to 6 km); ...
... published research shows that more patients with end-stage ... hemodialysis as their initial kidney replacement therapy over ... the study now available in Arthritis Care ... College of Rheumatology (ACR), also found that African ...
... device that combines two microimaging technologies can reveal ... biological activities that, in coronary arteries, could indicate ... of clots in arterial stents. In their ... Massachusetts General Hospital (MGH) investigators describe using an ...
... Special Surgery physician-scientists who focus on arthritis, lupus, vasculitis ... to Chicago this week to share their recent findings ... College of Rheumatology (ACR). Special Surgery investigators will ... care. Of the meeting,s highlights, results from the nine-year ...
... appear to be stopping anti-TNF medications before surgery, but may ... a new study by researchers at Hospital for Special Surgery. ... diseases, including rheumatoid arthritis, and better timing of withdrawal prior ... "We need to do more studies to see ...
Cached Medicine News:Health News:New study challenges accepted approaches to research in senile dementia (Alzheimer's disease) 2Health News:New study challenges accepted approaches to research in senile dementia (Alzheimer's disease) 3Health News:Runners Can Relax About Holiday Feasting: Study 2Health News:Most lupus nephritis patients with end-stage renal disease opt for hemodialysis therapy 2Health News:Combined arterial imaging technology reveals both structural and metabolic details 2Health News:Hospital for special surgery physician-scientists share advances in rheumatology research 2Health News:Hospital for special surgery physician-scientists share advances in rheumatology research 3Health News:Hospital for special surgery physician-scientists share advances in rheumatology research 4Health News:Hospital for special surgery physician-scientists share advances in rheumatology research 5Health News:Hospital for special surgery physician-scientists share advances in rheumatology research 6Health News:Tweaking withdrawal of rheumatoid arthritis medications before surgeries may reduce disease flares 2Health News:Tweaking withdrawal of rheumatoid arthritis medications before surgeries may reduce disease flares 3
The RU is a low profile implantable bipolar tined permanent pacing lead for stimulation of either the atrium (J model) or the ventricle (straight model)....
The Petite leads are low profile (4.8F lead body diameter) implantable endocardial pacing leads which are manufactured using a new proprietary hexafilar coil for permanent stimulation of the ventricl...
The Vitatron Excellence S+ lead series are endocardial leads providing excellent reliability and optimal pacing characteristics....
... Impulse II lead series are silicon ... extend the longevity of the pacemaker ... The high impedance of the lead ... electrode surface, combined with the elution ...
Medicine Products: